Concomitant asthma medications in moderate-to-severe allergic asthma treated with omalizumab

Omalizumab therapy initiation was associated with decreased doses of ICS, SABA, and LTM over 2 years of follow-up for the majority of patients in a “real-world” cohort study of moderate-to-severe allergic asthma patients.